Mark W. Hahn, Chief Financial Officer at Verona Pharma plc (VRNA), sold 259,344 shares at $4.38 ($1.1M) on 2024-11-01, disclosed to the SEC on 2024-11-05.
Scheduled sale ($1.1M) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $4.38 | 48,888 | $214K | 18.8% |
| 2 | $4.38 | 48,888 | $214K | 18.8% |
| 3 | $4.39 | 80,784 | $355K | 31.2% |
| 4 | $4.39 | 80,784 | $355K | 31.2% |
| Total | $4.39 avg | 259,344 | $1.1M | 100% |
| Filing → |
| VRNA | SELL | 2025-05-29 | $7.5M | — | Filing → |
| VRNA | SELL | 2025-05-05 | $7.0M | — | Filing → |
| VRNA | SELL | 2025-05-01 | $1.6M | — | Filing → |